OPAL-HK
Patiromer in Patients with CKD and Hyperkalaemia on RAAS Inhibitors
Patient / Population Intervention / Exposure Comparison Outcome
In 243 patients with CKD and hyperkalaemia on RAAS inhibitors, patiromer lowered serum potassium and recurrent hyperkalaemia compared with placebo withdrawal.
N
243
Design
Single-blind, two-phase trial with randomised withdrawal
Endpoint
Change in serum potassium; recurrent hyperkalaemia
Relevance
3
ResultPotassium −1.01 mmol/L (p<0.001); recurrence 15% vs 60% on withdrawal (p<0.001).
Weir MR, et al. N Engl J Med. 2015;372(3):211-221. 10.1056/NEJMoa1410853
Discussion & critique
Enabled continuation of RAAS inhibitors despite hyperkalaemia; led to approval of patiromer.